Pipeline news

• Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization

  23 February 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the enrollment of the first patient in a Phase 3 clinical trial of IV ganaxolone (RAISE trial) for the treatment of refractory status epilepticus (RSE), a life-threatening occurrence of continued or intermittent seizures lasting more than five minutes in duration without recovery of consciousness. RSE is considered a medical emergency that can cause permanent brain damage or death if not quickly controlled.

• Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

  19 February 2021

  

  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has in-licensed the rights for AT-527 for the treatment of COVID-19 in Japan from Roche (SIX: RO, ROG; OTCQX: RHHBY). 

• binx health Enters into Distribution Agreement for National Launch of the FDA-cleared binx io

  16 February 2021

  

  A first-of-kind FDA-cleared infectious disease platform, the binx io provides results in about thirty minutes, which enables diagnosis and treatment of chlamydia (CT) and gonorrhea (NG) to take place in a single visit. The binx io’s test performance has been demonstrated to be on par with central-laboratory testing.

• Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

  16 February 2021

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that David M. Brown, M.D. delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD”.

• Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

  08 February 2021

  

  Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide prodrug platform.

• Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

  04 February 2021

  

  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients in the United Kingdom (UK), Ireland and other countries. AT-527 is an orally administered, direct-acting developmental antiviral agent derived from Atea’s purine nucleotide prodrug platform.

• OCON Healthcare Announces Positive Long-Term efficacy and safety data on over 100K users of its Smart IUB Ballerine Hormone-Free Contraceptive

  27 January 2021

  

  OCON Healthcare, a women’s health company which develops, manufactures and commercializes innovative 3D intrauterine drug delivery devices based on its patented IUB (Intra-Uterine Ball) platform, announced new positive world-wide data exploring the efficacy and safety of IUB Ballerine, the company’s smart 3D hormone-free intrauterine contraceptive.

• Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus

  26 January 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the enrollment of the first patient in a Phase 3 clinical trial of IV ganaxolone (RAISE trial) for the treatment of refractory status epilepticus (RSE), a life-threatening occurrence of continued or intermittent seizures lasting more than five minutes in duration without recovery of consciousness. RSE is considered a medical emergency that can cause permanent brain damage or death if not quickly controlled.

• Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications

  19 January 2021

  

  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has expanded its senior management team with the appointments of Jayanthi Wolf, Ph.D., Senior Vice President of Regulatory Affairs and Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications.

• Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas

  13 January 2021

  

  Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced the completion of the Phase 1b clinical trial conducted by the NCI with its lead clinical candidate zotiraciclib (ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. The trial investigated the safety and efficacy of ZTR, in combination with temozolomide (TMZ), in patients with recurrent high-grade gliomas.